|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A negative correlation between miR-122 and SerpinB3 or stem cell markers was found in HCC patients.
|
30717317 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conclusions<i>:</i> These data outline either HIF-2α and NEDDylation as two novel putative therapeutic targets to interfere with the procarcinogenic role of SerpinB3 in the development of HCC.
|
31817100 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the diagnostic sensitivity and specificity of protein induced by vitamin K absence or antagonist-II (PIVKAII), Glypican-3 (GP3), Cystatin B (CSTB), squamous cell carcinoma antigen 1 (SCCA1) and hepatocyte growth factor (HGF) as potential tumour markers for HCC in patients with alcoholic liver cirrhosis (ALC) using imaging techniques (MSCT and MRI) as reference standards.
|
28766361 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A close connection between SerpinB3 and DPPPIV has been identified, but further studies are required to better understand the mechanism by which these proteins communicate and exert metabolic effects in HCC.
|
29524519 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The rationale behind the selection of the peptide is that SB3, which is undetectable in normal hepatocytes, is overexpressed in hepatocellular carcinoma and in hepatoblastoma and has been proposed as a target of the hepatitis B virus (HBV).
|
27771945 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SerpinB3 is a hypoxia- and hypoxia-inducible factor-2α-dependent cystein protease inhibitor that is up-regulated in hepatocellular carcinoma and in parenchymal cells during chronic liver diseases (CLD).
|
28611447 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical data published so far and reviewed in this article seemingly suggest that neither total serum SSCA or its isoform 1 (i.e., SCCA1) may be ready for the prime time for management of patients with HCC.
|
25840050 |
2015 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Results from this study indicate that Myc was up-regulated by SerpinB3 through calpain and Hippo-dependent molecular mechanisms in transgenic mice and hepatoma cells overexpressing human SerpinB3, and also in human hepatocellular carcinomas.
|
26634820 |
2015 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SERPINB3 is a cysteine-proteases inhibitor up-regulated in a significant number of cirrhotic patients carrying hepatocellular carcinoma (HCC) and recently proposed as a prognostic marker for HCC early recurrence.
|
25544768 |
2015 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNAs and SerpinB3 in hepatocellular carcinoma.
|
24496037 |
2014 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis.
|
24809782 |
2014 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
T357A variant has a significantly higher frequency in nonencapsulated tumors than wild type SCCA1 (p = 0.034).The SCCA1, 2 mRNA is effective for detecting HCC and could be potentially applied in HCC diagnosis.
|
25150316 |
2014 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serpin SERPINB3 (SB3) found over-expressed in human hepatocellular carcinoma and in regenerating liver in mice has been shown to induce apoptosis resistance, epithelial-to-mesenchymal transition and increasing cellular invasion.
|
21737255 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Initially identified as a serological marker for advanced squamous cell carcinomas of the cervix, SCCA1 has also been found to be associated with other cancer types of epithelial or endodermal origins such as lung cancer, head and neck cancer, melanoma, and hepatocellular carcinoma.
|
21576355 |
2011 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Evaluation of serum squamous cell carcinoma antigen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients.
|
19112206 |
2009 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our data in this homogenous subset of patients- particularly that confirming no role for SCCA-1 - suggests that the choice of optimal biomarkers for HCC surveillance may be determined by the aetiology of underlying chronic liver disease.
|
18638391 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma.
|
14970861 |
2004 |